What if the future of cancer treatment is already here—but not yet available in the U.S.? In this powerful episode, we sit down with Dr. Matt Halpert, a leading cancer immunologist and the mind behind a groundbreaking double -loaded dendritic cell therapy that’s showing real promise—even for late stages of cancer. Dr. Halpert spent over a decade researching immunotherapy at Baylor College of Medicine. Today, he’s helping patients access this innovative treatment at the Immunocine Cancer Center in Mexico, where it’s already being used while clinical trials continue in the U.S. You’ll learn: How dendritic cell therapy works to reprogram the immune system to target cancer Why this therapy is different from other immune-based or checkpoint treatments Where it’s available now—and how patients are accessing it outside the U.S. What it could mean for people who can’t afford to wait for FDA approval Click to schedule a call with a Heal Navigator advisor to talk through your options. Subscribe for more expert interviews, patient stories, and emerging therapies in integrative cancer care.